Trial Profile

Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 25 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 2202083A (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine; Meningococcal vaccine group C conjugate
Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal group C infections; Pertussis; Poliomyelitis; Tetanus
Focus Pharmacodynamics
Sponsors GlaxoSmithKline; GSK

Most Recent Events

07 Oct 2009 Actual patient number (16) added as reported by ClinicalTrials.gov.
22 Aug 2009 Planned end date changed from 1 Sep 2010 to 1 Jun 2009 as reported by ClinicalTrials.gov.
20 Aug 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com